- Thank Congress for Recognizing the Value of NIH in FY 2018
You spoke and they listened, now it’s time to thank Congress for recognizing the impact that NIH and public health funding has on your research and the patients you treat. Please send a thank you message to your legislators for the 8.8% funding increase for NIH in the final FY 2018 spending bill.
- Contact Your Senators in Support of Sickle Cell Disease Legislation
Legislation to help improve outcomes for patients suffering from sickle cell disease (SCD) has successfully passed out of the House of Representatives and companion legislation has been introduced in the Senate. The Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018 aims to improve understanding of health care system utilization patterns of people with SCD and establish cost-effective practices to improve and extend the lives of patients.
- Contact Your Elected Officials in Support of CDC Funding
Your elected officials need to hear from you about the importance of the Prevention and Public Health Fund.
- Contact Your North Carolina State Senator in Support of H. 206
The Cancer Treatment Fairness Act (H.206) would require any health plan that provides coverage for cancer chemotherapy treatment to provide coverage for orally administered and self-injectable anticancer medications at a cost no less favorable than the cost of IV, port-administered, or injected anticancer medications. It is important you reach out to ask for your North Carolina state Senator's support.
- Urge your Representative to Support the Cancer Drug Parity Act
Legislation has been introduced in the U.S. House of Representatives that would ensure that patients enrolled in certain federally regulated health plans have access and insurance coverage for all anti-cancer regimens. Your Senators and Representative need to cosponsor these bills in order for them to be considered by the full Congress.
- Contact Your Michigan State Senator to Support SB 492
Legislation has been introduced in the Michigan Legislature that would ensure that patients have access and insurance coverage for all anti-cancer regimens regardless of the form that they take. Senate Bill 492 would require any health plan that provides coverage for cancer chemotherapy treatment to provide coverage for orally administered and self-injectable anticancer medications at a cost no less favorable than the cost of IV, port-administered, or injected anticancer medications.